|
Apr 10
|
How BioCryst Pharmaceuticals, Inc. (BCRX) Stock Stands Out in a Strong Industry
|
|
Mar 1
|
Is BioCryst Pharmaceuticals, Inc. (BCRX) the Best Small-Cap Stock to Buy Now?
|
|
Feb 27
|
BioCryst (BCRX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
|
|
Feb 26
|
Here's Why BioCryst (BCRX) Could be Great Choice for a Bottom Fisher
|
|
Feb 26
|
Wall Street Analysts Predict an 84.18% Upside in BioCryst (BCRX): Here's What You Should Know
|
|
Feb 24
|
BioCryst: Q4 Earnings Snapshot
|
|
Feb 24
|
BioCryst Reports Fourth Quarter and Full Year 2024 Financial Results and Upcoming Key Milestones
|
|
Feb 24
|
BioCryst Announces Positive Results from APeX-P Trial for ORLADEYO® (berotralstat) in Pediatric Patients with Hereditary Angioedema Aged 2 to <12 Years
|
|
Feb 17
|
BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
|
|
Feb 12
|
BioCryst Launches ORLADEYO® (berotralstat) in Portugal
|
|
Feb 10
|
Exploring Three High Growth Tech Stocks In The United States
|
|
Feb 10
|
BioCryst to Present New ORLADEYO® (berotralstat) Results from APeX-P Pediatric Trial at 2025 American Academy of Allergy, Asthma & Immunology / World Allergy Organization Joint Congress
|
|
Feb 10
|
BioCryst to Report Fourth Quarter 2024 Financial Results on February 24
|
|
Jan 14
|
BioCryst price target raised to $12 from $10 at Evercore ISI
|
|
Jan 10
|
Exploring High Growth Tech Stocks In January 2025
|
|
Jan 10
|
BioCryst Announces Preliminary Full Year 2024 ORLADEYO® (berotralstat) Net Revenue of $437 Million (+34 percent y-o-y)
|
|
Jan 7
|
BioCryst to Present at 43rd Annual J.P. Morgan Healthcare Conference
|
|
Oct 11
|
Is BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) The Top Stock With Improving Technical Ratings According To Piper Sandler?
|
|
Oct 10
|
BioCryst to Present New Real-World Evidence on Long-Term Prophylaxis in HAE, including ORLADEYO® (berotralstat), at the American College of Allergy, Asthma & Immunology 2024 Annual Scientific Meeting
|
|
Oct 9
|
BioCryst Pharmaceuticals, Inc. (BCRX) Surpasses Revenue Expectations by $11 Million in Q2
|